The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
Pfizer Inc. announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the… read more.
The EMA revealed that Pfizer had withdrawn its application submitted on December 20, 2024, for variation to the marketing authorisation for Ngenla to treat adults with growth hormone… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Bosulif…. read more.
NICE (UK) Nirmatrelvir plus ritonavir is recommended as an option for treating COVID‑19 in adults, only if they: i) do not need supplemental oxygen for COVID‑19 and, ii)… read more.
Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of… read more.
Hympavzi (marstacimab) from Pfizer has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat haemophilia A or B in adult and paediatric patients…. read more.
Pfizer announced that the FDA accepted for review a Biologics License Application (BLA) for MenABCWY, its investigational pentavalent meningococcal vaccine candidate. Pfizer submitted MenABCWY for the prevention of… read more.
Pfizer Inc will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30… read more.
Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF)… read more.
Pfizer Inc. announced positive results from the Phase III TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
